A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]
Phase 2
20 Years
N/A
20 Years
N/A
Not Enrolling
Both
Non Small Cell Lung Carcinoma
Both
Non Small Cell Lung Carcinoma
Trial Information
A Randomised, Double-blind, Parallel-group, Dose Finding Study to Assess the Efficacy and Safety of ZD6474 in Patients With Advanced, Metastatic, or Recurrent NSCLC Who Have Failed Previous Chemotherapy Regimens, at Least One of Which Contained Platinum [Title Abbreviated]
Inclusion Criteria:
- Provision of written informed consent.
- Life expectancy of 12 weeks or longer.
Exclusion Criteria:
- Pregnancy, breast feeding or female patients wishing to become pregnant.
- Treatment with a non-approved or investigational drug within 30 days before enrolment
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Outcome Measure:
To assess the objective response rates (by RECIST) to ZD6474 100, 200 and 300 mg/day respectively
Principal Investigator
AstraZeneca Japan Medical Director, MD
Investigator Role:
Study Director
Investigator Affiliation:
AstraZeneca
Authority:
Japan: Pharmaceuticals and Medical Devices Agency
Study ID:
D4200C00039
NCT ID:
NCT00252746
Start Date:
December 2004
Completion Date:
January 2007
Related Keywords:
- Non Small Cell Lung Carcinoma
- NSCLC
- Non Small Cell Lung Cancer
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
Name | Location |
|---|
